Table 3.
COVID-19–specific therapies received
n (%) | |
---|---|
Hydroxychloroquine | 76 (64) |
Azithromycin | 59 (50) |
Tocilizumab | 15 (13) |
Lopinavir and ritonavir | 12 (10) |
Convalescent plasma | 11 (9) |
Favipravir | 11 (9) |
Remdesivir | 5 (4) |
IVIG | 4 (3) |
Chloroquine | 3 (3) |
Other/unknown | 39 (33) |